

## Keyword Index for Volume 106

- 20S proteasome 904  
22Rv1 166  
4EGI-1 1660  
8-oxodG 344  
ABCB1 1395  
ABCG2 1320  
abdominal cancer 490  
*ABL1* 157  
acidity 1280  
acute myeloid leukaemia 475  
adenoma 517  
adenosine triphosphate-based chemotherapy response assay 53  
adhesion 1535  
Adjuvant! Online 1760  
adjuvant 32  
adjuvant chemotherapy 1239, 1268  
advanced 1068  
advanced breast cancer 440  
advanced gastric cancer 1039  
afatinib 6  
age 1068, 1353  
AIDS 447  
Akt 1196  
alcohol 592, 1881  
ALDH1 846  
ALK 1100  
Amphiregulin 1406  
anaemia 909  
anal carcinoma and survival 756  
anchorage-independent growth 553  
angiogenesis 314, 896, 1089, 1153, 1495, 2004  
angiotensin II-converting enzyme inhibitor 290  
angiotensin II receptor blocker 290  
animal exposure 966  
*ANPEP* 157  
antiangiogenesis 678  
antifungal 1626  
anti-HER2 therapy 673  
apoptosis 314, 693, 711, 763, 839, 858, 1288, 1499, 1551, 1953  
arginine 1481  
arginine deiminase 324, 1481  
argininosuccinate synthetase 324  
aromatase inhibitor 1062, 1618  
asbestos 575, 1016  
aspirin 1564  
ataxia telangiectasia 262  
*ATM* 262  
atrasentan 284  
attitudes 1907  
attributable fractions 1346  
atypical endometrioid hyperplasia 1297  
aurora kinase A 748, 1798  
automated counting method 383  
autophagy 324, 693, 711  
avoidable deaths 1846  
awareness 1907  
AZD2281 468  
 $\beta$ -catenin 1395  
barasertib 858  
Bcl-2 gene family 839  
beta2-Microglobulin 1239  
beta-catenin 517  
bevacizumab 453, 468, 799, 1718, 1926  
BH3 mimetic 711  
biglycan 1214  
bile duct cancer 1011  
bile reflux 1342  
biliary tumour 1011  
BIM 763  
biomarker 18, 85, 133, 148, 189, 199, 414, 460, 733, 955, 1039, 1153, 1160, 1506, 1718, 1989, 1960  
bladder cancer 222, 366, 496, 1177, 1187, 1891  
bone marrow stroma 1689  
bortezomib 333  
BRAF 939  
brain metastases 25, 440, 1850  
brain tumour 1702  
*BRCA1/2* mutation carriers 2016  
*BRCA1* 775, 1234, 1697  
*BRCA1/2* 780  
*BRCA2* 775  
breast/ovarian cancer risk 2016  
breast cancer 6, 25, 189, 248, 262, 375, 389, 397, 525, 592, 673, 780, 826, 916, 923, 1045, 1053, 1062, 1117, 1166, 1234, 1361, 1367, 1605, 1611, 1618, 1675, 1790, 1850, 1907, 1910, 1917  
breast cancer risk factors 996  
breast cancer subtype 1107  
breast-conserving surgery 1160  
breast density 996  
breast neoplasms 1560  
breast tumour cells 693  
bystander effect 889  
CA-125 633  
cachexia 1583  
CA IX 916  
calcifications 525  
calcium 1335  
cancer cell resistance 1648  
cancer cell viability 116  
cancer drug targets 254  
Cancer Referral Guidelines 436  
cancer registry 1910  
cancer screening 1361  
cancer stem cell 99, 1320, 1512, 1997  
cancer targets 1123  
cap-dependent translation 1660  
CAPIRI 453  
carboplatin 70, 633, 1728  
carboplatin resistance 482  
carcinoma 1495  
carcinomatous meningitis 440  
case-control study 447, 1331, 1346  
caspases 1499  
Cav-1 1187  
CCP score 1095  
CD133 1997  
CD151 923  
CD24 846  
CD44 846  
CD46 1543  
CD59 1543  
CD55 1543  
cell cycle 693  
cell cycle genes 1095  
cell death 711  
cell death mechanisms 1766  
CellSearch 508  
cellular immunotherapy 1123  
cervical cancer 1520, 1526, 1753  
cervical cancer screening 1571  
cervical cytology 817  
cervical intraepithelial neoplasia 45, 817, 975, 1753  
cetuximab 274, 793, 1406  
CHAC1 189  
checkpoint 429  
chemical genomics 254  
chemical proteomics 254  
chemoembolisation 1274  
chemokines 1306  
chemoprevention 45  
chemoradiotherapy 61  
chemo-response 1967  
chemosensitivity 333  
chemotherapy 274, 651, 658, 896, 947, 988, 1033, 1076, 1591, 1605, 1934  
chemotherapy resistance 1901  
childhood cancer 982  
childhood infections 1331  
childhood leukaemia 1556  
*Chlamydomonas psittaci* 966  
cholangiocarcinoma 1583  
chrysolite 575  
circulating-free DNA 375  
circulating tumour cells 375, 508, 939, 1605, 1790  
circulating tumour microemboli 508  
cisplatin 460, 658, 1027  
c-Jun 1997  
CK-19mRNA 1917  
class predictor 126  
clinical practice 1760  
clonal growth 1506  
clusterin 1945  
CML 1742, 1772  
CNS metastasis 397  
CNS symptoms 839  
coeliac disease 217  
cohort 210, 217, 596, 1004, 1011, 1842  
colon cancer 748, 1239, 1268, 1395  
colon cancer cell lines 141  
Colorectal 1386, 1718, 1907  
colorectal adenoma 608  
colorectal cancer 18, 126, 133, 141, 227, 517, 793, 799, 805, 931, 1320, 1335, 1374, 1431, 1499, 1564, 1713, 1722, 1735, 1826, 1833, 1875, 1926, 2010  
colorectal cancer liver metastases 1274  
colorectal cancer screening 1424  
combination chemotherapy 1728  
combination therapy 107, 1386, 1742, 1779  
common variants 389  
comorbidity 1353, 1860  
competing risks 1846  
complex intervention 826  
confidence interval 1846  
conformal radiotherapy 61  
controlled clinical trials 1259  
copy number 748  
cost 1045  
cost-effectiveness 805, 1100, 1571  
C-reactive protein 702  
crizotinib 1100  
crocidolite 1016  
CRP 1866  
CXCL12 1306, 1520  
CXCR2 1833  
CXCR4 1306, 1520  
CXCR7 1520  
cyclin-dependent kinase 133  
cytochrome-*c* 889  
cytokines 1134  
cytology 975  
cytotoxic 1379  
D310 mutation 1506  
dacarbazine 85  
dasatinib 85  
data integration 1107  
DCE-MRI 1926  
DCIS 1160, 1506, 1611  
decision 1045  
decision aid 1053  
decision-making 1053

- definitions 1262  
 definitive RCT 826  
 delayed infection 1556  
 deletion 719  
 dendritic cells 546  
 depsi-peptide 116  
 detection 436, 1605  
 diabetes 1374  
 diagnosis 733, 904, 909, 982, 1068, 1431, 1556, 1940  
 diagnostic intervals 1262  
 diet 603, 608, 1891  
 dietary fat 596  
 diffusion-weighted magnetic resonance imaging 1638  
 diindolylmethane (DIM) 45  
 disease-free survival 955  
 disease progression 1249  
 disseminated tumour cells 375  
 DMXAA 1134  
 DNA damage response 429  
 DNA methylation 248, 414, 585  
 DNase 206  
 docetaxel 858, 1469  
 dormancy 375  
 dose escalation 678, 1598  
 double-strand DNA repair 1460  
 doublet 658  
 doxorubicin 916  
 driver-network 1107  
 drug discovery 254  
 drug–drug interaction 1772  
 drug resistance 1089, 1901  
 drug sensitivity 116, 867  
 DSC1 756  
 dual erbB protein kinase inhibitor family 666  
 ductal carcinoma *in situ* 1611, 1675  
 duodeno-gastro-oesophageal reflux 1342  
 dynamic equilibrium 1512  
  
 E7080 1598  
 early breast cancer 1760  
 early detection of cancer 975  
 early diagnosis 1262  
 EBNA1 206  
 EBV 1980  
 E-cadherin 756  
 education of patients 651  
 EEF1A1 166  
 EEF1A2 166  
 effectiveness 1045  
 effectiveness of the QoL system 826  
 EGFR HER2 719  
 EGFR PharmDx 883  
 EGFRvIII 883  
 eIF4F complex 1660  
 elderly 274, 1353  
 electromagnetic fields 307  
 ELISA 1495  
 EML4–ALK 763  
 EMT 1196, 1735  
 endometrial cancer 1551, 1682  
 endometrioid endometrial cancer 1297  
  
 endothelin axis 284  
 enzootaurin 867  
 EPIC 1866  
 epidemiologic methods 569  
 epidemiologic studies 970  
 epidemiology 1860  
 epidermal growth factor receptor 666, 883, 1100, 1196, 1367, 1406, 1520  
 epigenetically silenced 482  
 epigenetics 248, 414, 1446  
 epinephrine 460  
 Epiregulin 1406  
 epithelial cells 1205  
 epithelial mesenchymal transition 1512  
 epithilones 70  
 Epstein–Barr virus 206  
 ER $\alpha$  1682  
 ER positive 1798  
 erythropoiesis-stimulating agents 1249  
 erythropoietin receptor 1249  
 ESFT cell lines 1288  
 ethnicity 1361  
 everolimus 876, 1039  
 evolutionary game theory 174  
 Ewing's sarcoma family of tumours 1123, 1224  
 exemestane 1062  
 exon array 538  
 expected survival 1854  
 expression profiling 538, 1095  
 extracellular 1453  
 extracellular signal-regulated protein kinase (ERK) 1997  
 eye 1171  
 EZH2 243  
  
 FADD 1989  
 faecal immunochemical test 805  
 faecal occult blood tests 1424  
 family history 780  
 Fas/Fas L upregulation 1288  
 FBXW7 182  
 FDG-PET/CT 1926  
 fertility 1053  
 FFPE 538  
 FGFR2 727  
 FGFR3 1406  
 fine-needle aspiration biopsy 562  
 first-in-human 666  
 five subtypes 923  
 flexible sigmoidoscopy 805  
 FLT3 475  
 FLT3-ITD 475  
 fluconazole 1626  
 FOBT 805  
 FOLFIRI 453  
 FOLFOX therapy 126  
 follow-up 1611  
 food supplement 45  
 FUS-DDIT3 1976  
 fusogenic glycoprotein 496  
  
 gallstones 1011  
 gamma-glutamyltransferase 1551  
 gamma-glutamyltranspeptidase 1551  
 gastric adenocarcinoma 733  
 gastric cancer 210, 585, 685, 727, 740, 1469, 1535, 1591, 1668  
 gastric resection 1342  
 gastric surgery 1342  
 G<sub>D2</sub> 1123  
 gefitinib 1148, 1196  
 gemcitabine 1934  
 geminin 1798  
 gene amplification 727  
 gene-body 248  
 gene expression 867, 1648, 1967  
 gene mutations 1648  
 genetic testing 1234  
 gene transfer 1123  
 genomic stability 1297  
 genotype 1591  
 $\gamma$ H2AX 1807  
 Glasgow Prognostic Score 279  
 glioblastoma 1702  
 glioma 538  
 glucose 227  
 glutathione 1551  
 glutaraldehyde 1682  
 GPRD 233  
 growth factors 1033, 2004  
 $\gamma$ -secretase inhibitor 1953  
 GSK-3 $\beta$  1196  
  
 HA14-1 711  
 haeme iron 608  
 HDAC-inhibitor 116, 1682  
 head and neck cancer 1526  
 head-neck cancer radiotherapy 846  
 health personnel 651  
 health services research 1021  
 Hedgehog signalling pathway 1177  
 heparanase 1486  
 hepatocellular carcinoma 307, 1439  
 hepatocellular carcinoma metastasis 1486  
 HER2 6, 1367, 1453  
 Her2/neu 1543  
 HER2 + 25, 32  
 heritability 389  
 hereditary 1460  
 histamine-2-receptor antagonists 233  
 histone deacetylase inhibitor 77, 107  
 histone methyltransferase 243  
 HIV 447  
 HLA class I 1980  
 HMW-MAA 939  
 homeostasis model assessment-insulin resistance 227  
 hormone receptor-positive 1760  
 HPV vaccination 1571  
 human 1224  
 human 8-oxoguanine DNA glycosylase 344  
 human epidermal growth factor receptor 2 (HER-2)-positive breast cancer 440  
  
 human papillomavirus (HPV) 45, 222, 358, 817, 975, 1526, 1753  
 human polyomavirus 222  
 hybrid capture 975  
 hydroxyapatite 525  
 hypergastrinaemia 233  
 Hypertension 1718  
 hypoxia 314, 904, 916  
 hypoxia hypoxia-inducible factor-1 1638  
  
 ICR10 883  
 IFN- $\alpha$  284  
 IgA 206  
 IGF1R 1367  
 IGFBP-3 1004  
 IGF-I 1004  
 IHC4 1760  
 IL23R 517  
 IL-6 1866  
 IL-8 1833  
 imaging biomarker 619  
 Imatinib 1772  
 immortalisation 1205  
 immune-modulation 896  
 immunodeficiency 447  
 immunohistochemistry 141, 883, 947, 1033, 1926  
 immunotherapy 793, 896, 988  
 imputation 1068  
 incidence 962, 970, 1335, 1753, 1850  
 India 962  
 indole-3-carbinol (I3C) 45, 333  
 indoleamine 2,3-dioxygenase 1 141  
 inequalities 1361  
 infections 1556, 1626  
 inflammation 199, 217, 1439, 1866, 2010  
 inflammatory markers 1424  
 iNOS 889  
*in situ* hybridisation 1790  
 insulin resistance 1335  
 integrin- $\beta$ 1 846  
 integrin signalling 1535  
 inter-conversion 1512  
 interferon- $\alpha$  1742  
 interleukin-6 1583  
 internet 651  
 intolerance 1475  
 intragenic 248  
 intraperitoneal perioperative chemotherapy 460  
 invasion 148, 553  
 invasive margin 2010  
*in vivo* 324  
 ionising radiation 889  
 irinotecan 18, 1591  
 irreversible electroporation 490  
 ISET 508  
  
 Ki67 1798  
 kidney cancer 1475  
 kinase inhibitor 475  
 KIT 939  
 $\kappa$ -opioid receptor 1148

- KRAS 1406, 1722, 1826  
 KRAS mutation 748
- lapatinib 6, 25, 673  
 laser-induced thermotherapy 1274  
 LDH 799  
 LD radiolabelling 1027  
 let-7 1415  
 letrozole 1618  
 leukocyte 585  
 life change events 1560  
 Lin28 1415  
 Lin28B 1415  
 liposomal doxorubicin 1027  
 liver metastases 1926  
 liver resection 53  
 LMP1 1980  
 LNCaP 166  
 localised prostate cancer 1095  
 locally advanced 61  
 locally advanced cervical cancer 39  
 low-risk GTN 1089  
 lung cancer 447, 575, 867, 1100, 1153, 1346, 1854, 1907  
 lymphangiogenesis 348  
 lysate therapy 92
- M30 ELISA 1766  
 M65 ELISA 1766  
 machine learning algorithm 126  
 magnesium 1335  
 magnetic resonance spectroscopy 1638  
 malignant melanoma 553  
 malignant pleural mesothelioma 1027  
 mammography 525  
 marker protein patterns 1297  
 mass screening 805, 970  
 mathematical model 1280, 1742  
 matrix metalloproteinase 1486  
 matrix metalloproteinase 1431, 1495  
 MCM2 1798  
 mCRC 453  
 MCV 1166  
 MDA-7/IL-24 1976  
 meat 603, 608  
 meat mutagens 608  
 MEK 1386  
 melanocyte 553  
 melanoma 85, 939, 970, 1134, 1446, 1481  
 melatonin 1288  
 menarche 210  
 menopause 210  
 mental health 1842  
 Merkel cell carcinoma 1166, 1314  
 Merkel cell polyomavirus 1314  
 mesenchymal stem cells 1901  
 mesothelioma 575, 1016  
 meta-analysis 603, 1881  
 metastasis 133, 148, 174, 348, 1446, 1535, 1668, 1689, 1718  
 metastatic colorectal cancer 274
- metastatic renal cell carcinoma 646, 1587  
 metformin 1117, 1374  
 methodology 854  
 methods 1262  
 Microarray 1779  
 microcalcifications 525  
 micro CT 496  
 micrometastasis 1675  
 micronucleus test 780  
 micronutrients 1891  
 microRNA 182, 366, 405, 740, 1526, 1826  
 microRNA expression 768  
 microsatellite analysis (MSA) 1171  
 microsatellite instability 1239  
 microvesicles 896  
 microvessel 702  
 Mifamurtide 14  
 mineralisation 525  
 miR-143 366  
 miR-145 366  
*miR-1* and *miR-133a* 405  
 miR-328 1320  
 mitochondria 1224  
 mitochondrial DNA 1506  
 mitotic spindle 307  
 MMP16 1320  
 model 1045  
 molecular clustering 538  
 molecularly targeted agents 854  
 molecular marker 562, 909, 1177  
 MOLM-13 475  
 monosomy 3 1171  
 morphology 1875  
 mortality 1560, 1842  
 mRCC 284  
 MRI 1960  
 Mrna 1790  
 MRP-1 1224  
 MTHFR 677 C4T polymorphism 2016  
 mTOR 876, 1386  
 mTOR inhibitor 1475  
 multi-drug resistance 1224, 1395  
 multi-kinase inhibitor 1722  
 multiparametric imaging 619  
 multiple 1068  
 multiple myeloma 546, 1660  
 multiple risk-allele GWA replication 389  
 mumps 1331  
 mutation screening 1697  
 MV4-11 475  
 myxoid liposarcoma 1976
- naevus 553  
 Na,K-ATPase 1807  
 Nanog 1702  
 nasopharyngeal carcinoma 206  
 NAV3 517  
 necrosis 702  
 needle biopsy 1095  
 neoadjuvant chemotherapy 53
- nephrectomy 279  
 network analysis 1107  
 Neuroblastoma 1807  
 nitrate 608  
 nomogram 1083  
 non-Hodgkin's lymphomas 966, 988  
 non-seminoma 414  
 non-small cell lung cancer (NSCLC) 658, 763, 1148, 1953, 1989  
 normal mucosa 1495  
 Notch 1953  
 novel marine-derived compound 1379  
 Noxa 1660  
 NPC 1980  
 NSAIDs 1564, 1772  
 NSC-134754 1638  
 NT5E 1446  
 nurses 651
- occupational 1346  
 OCT-1 1772  
 Oct4 846  
 ocular adnexal marginal zone B-cell lymphoma epidemiology 966  
 oesophageal cancer 210, 702, 711, 955, 1342, 1415  
 oesophageal squamous cell carcinoma 876, 947  
 oestrogen receptor 1062, 1205, 1453  
 OGX-011 1945  
 olaparib 468  
 oncogene mutations 939  
 oncology trials 854  
 oncolytic HSV 496  
 one-step nucleic acid amplification assay 1675  
 oophorectomy 775  
 orchitis 1331  
 oropharynx 358  
 orphan drugs 14  
 orthotopic model 348, 496  
 Ouabain 1807  
 ovarian cancer 70, 189, 333, 482, 596, 629, 633, 1306, 1460, 1779, 1860, 1967  
 ovarian endometrioma 1205  
 overall survival 1374  
 OXi4503 1766  
 oxidative stress 99, 344
- P16 358  
 P2037 metastasis 1535  
 p53 397  
 p57<sup>Kip2</sup> 482  
 paclitaxel 633, 1728  
 PAI-1 366  
 pancreatic cancer 61, 233, 348, 508, 603, 1004, 1033, 1866, 1934, 1940  
 paraaortic lymphadenectomy 39  
 parity 210  
 PARP inhibitors 18, 1460  
 partial monosomy 3 1171
- pazopanib 629  
 PC-3 166  
 pegylated liposomal doxorubicin 633  
 pelvic lymphadenectomy 39  
 period analysis 1875  
 peritumoural 2010  
 personalised therapy 126  
 pertuzumab 1779  
 PFTK1 947  
 Pharmacokinetics 1598  
 pharmacokinetics 678  
 phase 1 468, 619, 629, 673, 1379, 1598, 1766  
 Phase II 453, 1027  
 phase III 1268  
 phase I TAK-285 666  
 PHB 1630 C4T polymorphism 2016  
 phenformin 1117  
 phosphoinositol 3 kinase inhibitor 107  
 physicians 651  
 PI3 kinase 1386, 1535  
 PKA 1648  
 PKC inhibitor 867  
 plasma 740, 768  
 plasma C-peptide 1335  
 platinum agents 1967  
 PLP2 307  
 PM00104 1379  
 Polycomb proteins 243  
 population-based 1011, 1564  
 population mixing 1556  
 population pharmacokinetics 460  
 positive predictive values 1940  
 PPAR $\gamma$  1486  
 PPAR $\gamma$  agonist 1702  
 prediction, biological marker 947  
 predictions 1016  
 predictive factors 799  
 preferences 638  
 primary care 1940  
 primary healthcare 982  
 primary invasive breast cancer 383  
 prodrug therapy 496  
 progesterin 1205  
 prognosis 133, 189, 297, 719, 904, 909, 923, 931, 1076, 1083, 1171, 1439, 1499, 1551, 1560, 1713, 1798, 1826, 1989  
 prognostic 1760  
 prognostic biomarkers 2004  
 prognostic factors 1095, 1177  
 prognostic index 1439  
 prognostic marker 1239  
 prognostic tool 646  
 progression-free survival 1587  
 proliferation 876  
 prophylaxis 1626  
 prospective studies 603  
 prostate cancer 99, 157, 166, 174, 217, 405, 436, 638, 768, 909, 1166, 1689, 1697  
 protein target identification 254

- proteomics 955  
 proton pump inhibitors 233  
*PSCA* 157  
 psychological stress 1560  
*PTEN/PI3K/Akt* pathway 1367  
*PTEN* 719  
 purine nucleoside phosphorylase (PNP) 405
- qPCR 157, 1605  
*Q-TWiST* 1587  
 quality-adjusted survival 1587  
 quality of life (QoL) 638, 646, 826, 1062, 1618, 1027  
 quiescence 1807
- RAD001* 876, 1475  
*RAD51C* 1460  
*RAD51D* 1460  
 radiation 297, 1512, 1953  
 radiation-induced 297  
 radiological 633  
 radiosensitivity 262  
 radiotherapy 262, 988  
 random error 1846  
 randomised, controlled trial 45, 1934  
 reactive oxygen species 314, 344  
 receptor tyrosine kinase inhibitor 666, 1598  
*RECIST* 854  
 recurrence 1160, 1560  
 recurrence-free survival 2004  
 regional lymph node metastasis 1735  
 regional variation 1846  
 registries 569  
*Regorafenib* 1722  
 regulatory strategy 14  
 regulatory T cells 546  
 relative survival 1846, 1854  
 release 1989  
 renal cancer 279, 904  
 renal cell cancer 1881  
 renal cell carcinoma 1945  
 renal pelvis: ureter 1083  
 renin-angiotensin system 290  
 response assessment 854  
 response rates 1021  
 retinoic acid receptor 77  
 retrospective review 1374  
 review 603  
*RhoGD12* 1187  
*rIL-21* 793  
 risk 1431, 1697  
 risk modification 996  
 risk prediction 199  
 risk profiles 436  
*RO* 5323441 678  
*ROS* 889  
*RT-PCR* 1177, 1314
- S-1* 1268, 1934  
*sagopilone* 70  
*salinomycin* 99  
 salivary gland cancer 719  
 salvage therapy 1591  
 sample size 1259  
*saracatinib* 1728  
 sarcoma 297  
*SATB2* 931  
 second-line chemotherapy 1469  
 scheduling 858  
 scoring system 1713  
 screening 733, 817, 1431, 1753  
 secondary malignancies 297  
 self-reporting 1910  
*seliciclib* 482  
*Selumetinib* 858, 1648  
 seminoma 414  
 sensitivity analysis 1854  
 sentinel lymph node 1314, 1675  
 sentinel node biopsy 39, 1045  
 serum 768, 1431  
 serum insulin 227  
 sexually transmitted disease 1753  
 side population cells 1320  
*sigma-2* receptors 693  
 signal regulated kinase 1453  
 signet ring cell carcinoma 1668  
*Sikkim* 962  
 skeletal muscle 1583  
 skin neoplasms 970  
 small cell lung cancer 324, 839  
 small-molecule library screening 254  
 smoking 447, 1854  
 snail 1196  
*SNP* 1495  
 socioeconomic position 988  
 socioeconomic status 1556  
 sodium bicarbonate 1280  
 soft tissue sarcoma 1076  
 solid tumours 77, 1598  
 somatic evolution 174  
*sorafenib* 1945  
*Sox2* 1702  
*sphingosine-1-phosphate* 909, 1453  
*sphingosine 1-phosphate* receptor 4 1453  
*sphingosine kinase* 1453  
 squamous cancer 358  
 squamous cell carcinoma 107  
*Src* 85, 1728, 1960  
*Src kinase* 1187  
 stage 1068  
 statins 685, 1689  
 stem cells 1702  
 stemness genes 1702  
 stratification 1259  
 stroma 1134, 2004
- subjective cognitive function 1618  
 subsite 1875  
*sunitinib* 646, 1469, 1587  
 surveys 1021  
 survival 39, 383, 569, 592, 646, 702, 955, 988, 1083, 1187, 1353, 1439, 1495, 1520, 1564, 1842, 1875, 1907, 2010  
 survival benefit 638  
*survivin* 763  
*SVM* 1735  
 symptoms 1940  
 synergy 333  
 systematic review 780  
 systemic inflammatory response 279, 2010
- tamoxifen* 1618  
*Taqman* 157  
 targeted agents 619  
 targeted therapy 148, 1826  
*taxanes* 685, 1967  
*TB-403* 678  
*T-DM1* 6  
*TDP1* 18  
*temozolomide* 858  
 testicular cancer 414  
 testicular germ cell tumours 1331  
*tetraspanin* 923  
*thalidomide* 1153  
 therapy 174, 1117  
 therapy response 1395  
*thioredoxin* 314  
 thyroid tumours 562  
 tissue inhibitors of metalloproteinase 1486  
 tissue recovery 490  
*TLS-CHOP* 1976  
*TNF* receptor 1866  
*TNM* stage 1713  
 tolerability 678  
 tonsillar cancer 1526  
*topoisomerase I* 18  
*TP53* 348  
 trade-off 638  
*trastuzumab* 6, 25, 32, 1543, 1779  
*trastuzumab* resistance 1367  
 treatment prediction 931  
 treatment-related morbidity 297  
 treatment response 53  
 triage 817  
*trichostatin A* 116  
*TRIP13* 157  
 triple-negative breast cancer 397, 1107, 1234  
 triple-negative disease 440  
 triplet 658
- tumour angiogenesis 1214, 1722  
 tumour biopsy 508  
 tumour budding 1713  
 tumour cells 1917  
 tumour endothelial cells 1214  
 tumour growth kinetics 854  
 tumour immunotherapy 92  
 tumour inflammatory infiltrate 702  
 tumour invasion front 141  
 tumour microenvironment 1833  
 tumour progression 1901  
 tumour staging 279, 1314  
 tumour-supernatants 896  
 tumour suppressor 405  
 tumour virus 429  
*TWiST* 1587
- UAPI* 1089  
 ubiquitin ligase 182  
*UDP-glucuronosyltransferase* 1591  
*UFT* 1268  
*UKCTOCS* 1910  
 unresectable 61  
 unresectable colorectal liver metastasis 53  
 upper-tract urothelial carcinoma 290  
 uptake 775  
 urine 768  
 urothelial carcinoma 1083  
 uterine serous cancer 1543  
 utility 638  
 uveal melanoma 1171
- value-based pricing 14  
 vascular disrupting agent 1766  
*VCA* 206  
*VEGF* 284, 1960  
*VEGF*-targeted therapy 1475  
*vinorelbine* 673  
 visual counting method 383  
*VLP* 92  
 vulvar brush 269  
 vulvar cytology 269  
 vulvar dysplasia 269  
 vulvar intraepithelial neoplasia 269
- web-based 1076  
*Weibull* model 646  
*Wittenoom* 1016
- XCL2* 307  
 xenografts 1117, 1134  
 xenograft tumours 333  
*XMRV* 1166
- young women 1053